MiNK Therapeutics announced a research collaboration with Autonomous Therapeutics, Inc. on October 8, 2024. This partnership aims to develop novel therapies for metastatic tumors by combining Autonomous’ precision encrypted RNA™ (encRNA) technology with MiNK’s iNKT cell therapies, MiNK-215 and agenT-797.
The collaboration will evaluate these technologies in metastatic solid tumor models, with the goal of developing treatments that specifically target metastatic cancer cells while sparing healthy cells. The companies plan to initiate a Phase 1 clinical trial in patients with treatment-refractory metastatic solid tumors, including microsatellite stable colorectal cancers, based on the preclinical results.
Dr. Jennifer Buell, President and CEO of MiNK, stated that this collaboration highlights the potential of both native and engineered iNKT cells to enhance clinical responses. Dr. Ariel Weinberger, CEO of Autonomous, added that their encRNA technology, such as AT313, is designed for precision targeting of solid tumors by sensing aberrant molecular signatures.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.